Клиническое исследование

BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer

NCT: NCT05977036 · RECRUITING

NCT IDNCT05977036

СтатусRECRUITING

Дата начала2024-09-25

Завершение2035-09-30

SponsorWashington University School of Medicine (OTHER)

First posted2023-08-04

Last updated2026-10-09

Краткое описание

This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with hormone receptor (HR) positive, HER-2 negative metastatic or unresectable breast cancer receiving first-line or second-line treatment.

Официальный источник

Открыть на ClinicalTrials.gov →

Данные получены через API ClinicalTrials.gov. Актуальный статус смотрите в официальной записи.